AU2003299191A1 - Enteric composition for the manufacture of soft capsule wall - Google Patents

Enteric composition for the manufacture of soft capsule wall

Info

Publication number
AU2003299191A1
AU2003299191A1 AU2003299191A AU2003299191A AU2003299191A1 AU 2003299191 A1 AU2003299191 A1 AU 2003299191A1 AU 2003299191 A AU2003299191 A AU 2003299191A AU 2003299191 A AU2003299191 A AU 2003299191A AU 2003299191 A1 AU2003299191 A1 AU 2003299191A1
Authority
AU
Australia
Prior art keywords
manufacture
soft capsule
capsule wall
enteric composition
enteric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003299191A
Other languages
English (en)
Inventor
Nachiappan Chidambaram
Aqeel A. Fatmi
Emadeldin M. Hassan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Patheon Softgels Inc
Original Assignee
Banner Pharmacaps Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banner Pharmacaps Inc filed Critical Banner Pharmacaps Inc
Publication of AU2003299191A1 publication Critical patent/AU2003299191A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
AU2003299191A 2002-10-01 2003-06-27 Enteric composition for the manufacture of soft capsule wall Abandoned AU2003299191A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41518702P 2002-10-01 2002-10-01
US60/415,187 2002-10-01
PCT/US2003/020579 WO2004030658A1 (en) 2002-10-01 2003-06-27 Enteric composition for the manufacture of soft capsule wall

Publications (1)

Publication Number Publication Date
AU2003299191A1 true AU2003299191A1 (en) 2004-04-23

Family

ID=32069824

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003299191A Abandoned AU2003299191A1 (en) 2002-10-01 2003-06-27 Enteric composition for the manufacture of soft capsule wall

Country Status (14)

Country Link
US (2) US8685445B2 (https=)
EP (2) EP2772250B1 (https=)
JP (1) JP5248739B2 (https=)
CN (1) CN1688294A (https=)
AU (1) AU2003299191A1 (https=)
CA (1) CA2500663C (https=)
CY (1) CY1118258T1 (https=)
DK (2) DK1545475T3 (https=)
ES (2) ES2500316T3 (https=)
HU (1) HUE031650T2 (https=)
MX (1) MXPA05003524A (https=)
PT (2) PT1545475E (https=)
SI (2) SI2772250T1 (https=)
WO (1) WO2004030658A1 (https=)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070082046A1 (en) * 2005-10-11 2007-04-12 Banner Pharmacaps, Inc. Enteric valproic acid
CA2627292C (en) 2005-10-26 2012-04-17 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
US8293270B2 (en) 2005-10-26 2012-10-23 Banner Pharmacaps, Inc. Lipophilic vehicle-based dual controlled release matrix system
US20070148248A1 (en) 2005-12-22 2007-06-28 Banner Pharmacaps, Inc. Gastric reflux resistant dosage forms
JP5183104B2 (ja) * 2006-06-19 2013-04-17 森下仁丹株式会社 口臭除去用多重ソフトカプセル
GB0706178D0 (en) * 2007-03-29 2007-05-09 Univ Aston Enteric pharmaceutical capsules
WO2009064814A2 (en) 2007-11-12 2009-05-22 Pharmaceutics International, Inc. Tri-molecular complexes and their use in drug delivery systems
WO2009062356A1 (en) * 2007-11-13 2009-05-22 Shanghai Huiyuan Vegetal Capsule Co., Ltd Non-gelatin enteric hard capsule shell and preparation method thereof
ES2552723T3 (es) 2008-05-06 2015-12-01 Dexcel Pharma Technologies Ltd. Formulación de bencimidazol estable
WO2010042499A1 (en) 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
CA2746887C (en) 2008-12-15 2016-07-05 Banner Pharmacaps, Inc. Methods for enhancing the release and absorption of water insoluble active agents
WO2010117873A2 (en) 2009-04-06 2010-10-14 Banner Pharmacaps, Inc. Progesterone solutions for increased bioavailability
JP2013519686A (ja) * 2010-02-12 2013-05-30 センシエント カラーズ エルエルシー 腸溶性コーティング組成物ならびにその製造法および使用法
EP2722104B1 (en) 2010-10-26 2018-03-07 Capsugel Belgium NV Bulk Enteric Capsule Shells
CA2870134C (en) 2012-05-02 2020-04-28 Capsugel France SAS Aqueous dispersions of hydroxypropyl methylcellulose acetate succinate (hpmcas)
MX2015011163A (es) * 2013-03-15 2016-02-17 Banner Life Sciences Llc Capsula entericas blandas que no contienen gelatina.
ES2706152T3 (es) * 2013-04-23 2019-03-27 Zx Pharma Llc Composición entérica de múltiples partículas revestida con subrevestimiento proteico
US9504656B2 (en) 2013-10-21 2016-11-29 Banner Life Sciences, LLC Pharmaceutical compositions for poorly soluble active ingredients
CA2926335C (en) 2013-10-30 2021-11-23 Banner Life Sciences Llc Enteric soft capsules comprising polyunsaturated fatty acids
US20160256399A1 (en) 2013-11-04 2016-09-08 Capsugel Belgium Nv Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
AU2015222880B2 (en) 2014-02-28 2016-11-24 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US10772842B2 (en) 2015-01-09 2020-09-15 Patheon Softgels Inc. Abuse-deterrent opioids
US10772841B2 (en) 2014-04-07 2020-09-15 Patheon Softgels Inc. Opioid abuse-deterrent controlled release formulations
US9775814B2 (en) 2014-06-20 2017-10-03 Patheon Softgels Inc. Enteric soft capsule compositions
US20150366814A1 (en) 2014-06-23 2015-12-24 Banner Life Sciences Llc All-natural enteric soft capsules comprising active ingredients
WO2015200563A1 (en) * 2014-06-26 2015-12-30 Banner Life Sciences Llc Enhanced bioavailability of polysaturated fatty acids
US9895333B2 (en) * 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
US10471152B2 (en) 2014-08-29 2019-11-12 Capsugel Belgium Nv Colloidal dispersion comprising HPMCAS
AU2015329446B2 (en) 2014-10-06 2017-03-16 Fuji Capsule Co., Ltd. Method of manufacturing enteric soft capsule
AU2015329445B2 (en) 2014-10-06 2017-11-30 Fuji Capsule Co., Ltd. Method of manufacturing enteric seamless soft capsule
WO2016057133A1 (en) * 2014-10-08 2016-04-14 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
EP3285764B1 (en) * 2015-03-31 2024-03-27 University of Vermont and State Agricultural College Triazolopyridazines for treating cryptosporidiosis
US10182993B2 (en) 2015-04-06 2019-01-22 Patheon Softgels Inc. Compositions for colonic delivery of drugs
WO2017136617A1 (en) 2016-02-04 2017-08-10 Cinrx Pharma, Llc Deuterated domperidone compositions and methods for therapy of disorders
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
PL239878B1 (pl) 2016-03-30 2022-01-24 Gdanski Univ Medyczny Wodna kompozycja oraz sposób wytwarzania dojelitowych elastycznych filmów do sporządzania kapsułek z wodnej kompozycji oraz dojelitowy elastyczny film do sporządzania kapsułek miękkich
NL2017219B1 (en) * 2016-07-22 2018-01-30 Rousselot B V Low cross-linking gelatine
EA201992116A1 (ru) 2017-03-08 2020-01-29 СИНРКС ФАРМА, ЭлЭлСи Фармацевтические составы флороглюцинола и триметилфлороглюцинола
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
US11980691B2 (en) 2018-03-15 2024-05-14 R.P. Scherer Technologies, Llc Enteric softgel capsules
CN108619523B (zh) * 2018-03-23 2020-06-30 浙江工业大学 一种可用于快速热塑包衣制剂的包衣膜片及其制备方法
WO2020144591A2 (en) * 2019-01-09 2020-07-16 Antony Benny Preparation of purified withanoside x from withania somnifera plant materials and its medicinal use for the treatment of health disorders
CN109566829A (zh) * 2019-02-11 2019-04-05 广东国方医药科技有限公司 牡丹籽油肠溶凝胶糖果及其制备方法
US11439653B1 (en) 2021-03-30 2022-09-13 Epalex Corporation Fospropofol formulations
US11628178B2 (en) 2019-03-26 2023-04-18 Epalex Corporation Fospropofol methods and compositions
US11478490B1 (en) 2021-03-30 2022-10-25 Epalex Corporation Fospropofol formulations
US11547714B2 (en) 2020-02-05 2023-01-10 Epalex Corporation Fospropofol salts, methods and compositions
BR112021022194A2 (pt) 2019-05-07 2021-12-28 Bausch Health Ireland Ltd Formulações líquidas para dosagem oral de metilnaltrexona
WO2021011177A1 (en) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Enteric proton pump inhibitor softgel capsule
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
CA3177250A1 (en) 2020-05-02 2021-11-11 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
CA3119012C (en) * 2021-05-18 2023-10-17 Gelentroceutics Inc. Formulation of intrinsically acid-resistant vegetarian-based and gelatin-based soft gel capsules for pharmaceutical/nutraceutical products
JP2025519816A (ja) 2022-06-21 2025-06-26 ニュートリション アンド バイオサイエンシズ ユーエスエー １，リミティド ライアビリティ カンパニー 硬質シェルカプセル、フィルム及びコーティングのためのフィルム形成遅延／腸溶配合物
CN121263207A (zh) * 2023-06-06 2026-01-02 R·P·谢勒技术有限公司 氨溴索液体调配物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826666A (en) * 1972-07-20 1974-07-30 Parke Davis & Co Enteric capsules
DE2340060A1 (de) * 1973-08-08 1975-02-20 Scherer Gmbh R P Magensaftresistente gelatinekapseln und verfahren zu deren herstellung
US4138013A (en) * 1976-08-27 1979-02-06 Parke, Davis & Company Enteric capsules
EG16027A (en) * 1982-03-26 1986-12-30 Warner Lambert Co Hydrophilic polymer composition for injection molding
US4790881A (en) 1982-03-26 1988-12-13 Warner-Lambert Company Molded hydrophilic polymer
DE3222476A1 (de) 1982-06-15 1983-12-15 Warner-Lambert Co., 07950 Morris Plains, N.J. Magensaftresistente weichgelatinekapseln und verfahren zu ihrer herstellung
US4518433A (en) 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4500453A (en) * 1984-06-29 1985-02-19 Dynagel Incorporated Cross-linked protein composition using aluminum salts of acetic acid
US4816259A (en) * 1987-02-12 1989-03-28 Chase Chemical Company, L.P. Process for coating gelatin capsules
US5194464A (en) * 1988-09-27 1993-03-16 Takeda Chemical Industries, Ltd. Enteric film and preparatoin thereof
US6482516B1 (en) 1993-07-20 2002-11-19 Banner Pharmacaps, Inc. Enrobed tablet
US5146730A (en) 1989-09-20 1992-09-15 Banner Gelatin Products Corp. Film-enrobed unitary-core medicament and the like
US5330759A (en) 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
KR20010012402A (ko) 1997-05-09 2001-02-15 세이지 파마슈티칼스, 인크. 안정한 약제학적 경구 투여형
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6193999B1 (en) * 1999-03-01 2001-02-27 Banner Pharmacaps, Inc. Gum acacia substituted soft gelatin capsules
DE19922537A1 (de) * 1999-05-10 2000-11-16 Roland Bodmeier Darreichungsform zur Applikation in Körperöffnungen
CA2386277A1 (en) * 1999-10-01 2001-04-12 Natco Pharma Limited An improved pharmaceutical composition and a process for its preparation
EP1184033A1 (en) 2000-09-01 2002-03-06 Warner-Lambert Company Pectin film compositions
AU2003274683A1 (en) * 2002-08-02 2004-02-23 Scitech Centre NOVEL pH DEPENDENT ROBUST ENTERIC POLYMERIC CONTAINER, AN IMPROVEMENT OVER EXISTING ENTERIC DOSAGE FORMS.

Also Published As

Publication number Publication date
DK1545475T3 (da) 2014-07-28
EP1545475B1 (en) 2014-07-16
HUE031650T2 (en) 2017-07-28
SI2772250T1 (sl) 2017-03-31
ES2609059T3 (es) 2017-04-18
PT1545475E (pt) 2014-09-16
CA2500663C (en) 2013-05-28
JP2006505542A (ja) 2006-02-16
US8685445B2 (en) 2014-04-01
EP2772250A1 (en) 2014-09-03
DK2772250T3 (en) 2016-12-05
US20140348879A1 (en) 2014-11-27
US9433585B2 (en) 2016-09-06
US20060165778A1 (en) 2006-07-27
JP5248739B2 (ja) 2013-07-31
ES2500316T3 (es) 2014-09-30
CA2500663A1 (en) 2004-04-15
CY1118258T1 (el) 2017-06-28
PT2772250T (pt) 2017-01-02
EP2772250B1 (en) 2016-09-28
WO2004030658A1 (en) 2004-04-15
MXPA05003524A (es) 2005-10-04
EP1545475A1 (en) 2005-06-29
CN1688294A (zh) 2005-10-26
SI1545475T1 (sl) 2014-10-30

Similar Documents

Publication Publication Date Title
AU2003299191A1 (en) Enteric composition for the manufacture of soft capsule wall
AU2003257550A1 (en) Soft capsule preparation
AU2002315779A1 (en) Soft capsules
AU2003218983A1 (en) Dynamic composition of restricted courses
AU2003280116A1 (en) Methods of making endoprostheses
IL163863A0 (en) Form of presentation for3-Ä(2-äÄ4-(hexyloxycarbonylamino-imino-methyl)-phenylaminoÜmethylü-1-methyl-1H-benzimidaz
AU2003231439A1 (en) Photostabilized soft capsule
AU2003260983A1 (en) Processes for the preparation of s-(-)-amlodipine
AU2002367890A1 (en) Process for the preparation of 4-methyl-thiazole-5-carbaldehyde intermediate
AU2003265373A1 (en) Preparation of aztreonam
AU2003298725A1 (en) Preparation of metallotexaphyrins
AU2003901844A0 (en) The generation of images
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2003243432A1 (en) Process of making phosphordiamidite compounds
AU2003293693A1 (en) Process for the preparation of bisphenols
AU2003240450A1 (en) Manufacture of ketopantolactone
AU2003255810A1 (en) Construction of lampshades
AU2002226616A8 (en) Preparation of pure 3-alkoxymethyl cephalosporins.
AU2003206318A1 (en) Blank for the preparation of denture parts
EP1386911A3 (de) Verfahren zur Herstellung von Acyloxybenzolsulfonaten
AU2003281158A1 (en) The treatment of emesis
EP1437347A3 (de) Verfahren zur herstellung von arylvinylhalogeniden und arylalkinen
IL165356A0 (en) Preparation of 4-haloalkylkylnicotinamides
PL356853A1 (en) Application of bacteriphages
AU2003226547A1 (en) Improved form of competition

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase